Tobacco smoke induces inflammation in smokers’ lungs, and chronic exposure results in lung tissue damage and destruction. The inflammation associated with COPD in humans is characterized as steroid insensitive. Viral and bacterial infection can cause acute exacerbation of COPD, which often results in hospitalization and increased health care costs. These exacerbation events are routinely treated with high-dose oral steroid therapy.
Charles River is developing models of COPD in mice that allow examination of compounds (both small molecule and biologics).